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Cytomegalovirus and Clostridium Difficile co-infec-
tion in severe ulcero-hemorrhagic colitis during
induction chemotherapy for acute lymphoblastic
leukemia
Here we describe the first case of a biopsy-
proven Cytomegalovirus ulcero-hemorrhagic colitis,
associated with Clostridium Difficile co-infection,
occurring during standard induction chemotherapy
for common B cell acute lymphoblastic leukemia.
We discuss the case and focalize clinical manage-
ment and diagnostic issues arising from it.Haematologica 2005; 90:(1)e1-e3
A previously healthy 39-year-old Caucasian male was
admitted to the hospital because of the diagnosis of com-
mon B-cell acute lymphoblastic leukemia (ALL), associat-
ed with t(1;19) chromosomal translocation. He was com-
menced on induction chemotherapy with daunorubicin,
vincristine and prednisone, according to the LAL-2000
protocol for ALL proposed by Italian multicentre group
GIMEMA. On day 14 after the beginning of chemothera-
py, owing to the onset of febrile neutropenia, intravenous
antibiotic therapy with ceftazidime and vancomycin was
initiated, obtaining a rapid clinical improvement. On day
26, the patient developed abdominal pain and several
episodes of diarrhea, with bright red blood mixed to
semiformed stool, followed by profuse rectorrhagia. The
patient was afebrile, neither nausea nor vomiting were
referred, and no signs of peritoneal irritation were found.
Stool samples were collected for microbiological analy-
ses. Urgent laboratory investigations were as follows:
hemoglobin level lowering from 9.5 g/dL to 7.8 g/dL in
24-hours; white blood cell count of 3.7×109/L, with a dif-
ferential leukocyte count showing severe lymphocytope-
nia; platelet count of 133×109/l, with normal coagulation
clotting times and unremarkable blood chemistry profile.
Packed erythrocytes were transfused; then an urgent
colonsigmoidoscopy permitted to identify three large lin-
ear ulcerations, the widest approximatively measuring 4
×1 cm, localized at the transition from the discending
colon to the sigmoid colon, in the transverse colon, and
in the coecum, respectively. The lesions were covered by
fibrinous-necrotic exudates and fibrin clots, but no
pseudomembranes were found (Figure 1A). 
Microscopic examination of multiple endoscopic biop-
sies performed at the borders of the lesions revealed an
inflammatory granulation tissue, containing distinct giant
cells with prominent intranuclear inclusion bodies.
Immunohistochemical staining with anti-
Cytomegalovirus (CMV) monoclonal antibody (clone
CCH2; Dako) resulted focally positive (Figure 1B). PCR
amplification of DNA extracted from formalin-fixed,
paraffin-embebbed bioptic specimens was positive for
CMV DNA. All other tissutal searches for herpesviruses,
mycotic forms, acid-fast bacilli and for common-B blast
cells infiltration yielded negative results. On day 27, both
CMV-pp65 antigenemia (2 positive cells/slide) and quali-
tative PCR amplification for CMV DNA on whole blood
resulted positive. At the same time, microbiological
analyses of stool samples showed negative results for
common intestinal pathogenic bacteria, virus, ova and
parasites, except for detection of Clostridium Difficile
(CD) A and B toxins by enzyme-linked immunoassay
(EIA). The patient was promptly started on a three-week
course of antiviral therapy with Foscarnet (180
mg/kg/die), preferred to ganciclovir because of the
reported minor hematotoxicity; moreover, intravenous
vancomycin and ceftazidime were withdrawn, and oral
metronidazole (1g/die) was started. The patient returned
to his normal bowel habits in ten days, with stool sam-
ples negative for CD toxins and with persistently nega-
tive CMV-pp65 antigenemia. The patient completed the
standard course of induction chemotherapy without
other relevant complications, obtaining hematological
and molecular complete remission of leukemia. After dis-
charge, control colonoscopy revealed healing ulcerations
and immunohistochemical assay for CMV antigen tested
invariably negative in all biopsy specimens. 
On day 70 from the beginning of induction chemother-
apy, the patient developed fever and interstitial pneumo-
nia with highly positive bronchoalveolar lavage fluid for
CMV-pp65 antigenemia, for which he was successfully
treated with ganciclovir (5 mg/kg twice a day, for three
weeks). At that time, he was not receiving chemotherapy
and his blood cell count was normal, except for mild lym-
phocytopenia. Then he underwent consolidation
chemotherapy and autologous bone marrow transplanta-
tion, without further complications, and with a persist-
ently negative CMV antigenemia, during the whole post-
transplant period. The patient is still in hematologic and
molecular remission, 20 months after the diagnosis.
Discussion 
CMV colitis is a well recognized complication in
acquired immunodeficiency syndrome (AIDS) as well as
in solid organ and bone marrow transplant (BMT) set-
tings. In other subsets of immunocompromised (IC)
patients, CMV colitis is a rare but equally serious disease.
To the best of our knowledge, only few cases have
described the occurrence of CMV colitis during anti-neo-
plastic treatment for solid tumors and hematologic malig-
nancies.1-5 In all of these cases, the diagnosis of CMV dis-
ease was obtained by an endoscopic biopsy of colonic
lesions, allowing tissutal identification of the virus. In one
of these cases, the diagnosis was also supported by the
positivization of high-level CMV antigenemia and, after
treatment of CMV colitis, the patient also developed
CMV-negative CD-associated pseudomembranous coli-
tis.4 Here we report the first case of biopsy-proven CMV
colitis occurring in the course of standard induction
chemotherapy for B-cell ALL. Our diagnosis, according to
the definition of CMV gastrointestinal disease,6 was
based on the identification of clinical and endoscopic fea-
tures associated with bioptical demonstration of CMV
infection by immunohistochemical analysis, also sup-
ported by the positivization of CMV antigenemia.
Nevertheless, a simultaneous CD infection was disclosed
by the isolation of both fecal CD toxins with highly spe-
cific enzyme immunoassay (EIA) test. It is known that a
problematic issue in the diagnostic process of CMV end-
organ disease arises when other pathogens are identified
together with CMV infection.7 Concerning the gastroin-
testinal disease, there are no clear indications for specific
and reliable evaluation of CMV and CD co-infection.
Indeed, in the case reported here, while CMV seems to
be strongly involved in the genesis of the colitis, leaving
no doubt about the occurence of an inflammatory disease
of the colonic mucosa driven by the virus, it appears
much more difficult to assess the pathogenic contribution
and clinical relevance of CD infection. In favour of a
causative role of CD is the evidence that CD is a common
cause of nosocomial diarrhea in IC patients. Consistent
with this, in a large retrospective study, 7% of hemato-
logic patients treated with myelosuppressive chemother-
apy showed clinical symptoms with EIA positivity for
CD-toxins.8 Moreover, our patient presented major risk
factors for CD colitis, such as prolonged treatment with
third generation cephalosporine, long-term hospital
admission and recent receipt of antineoplastic
chemotherapy.8,9 Against a major role of CD is the lacking
of endoscopic evidence of typical psudomembranous
colitis, which is commonly associated with the severe
clinical presentation of CD infection with frank hema-
tochezia.10 Moreover, other case series reported CD-tox-
ins EIA positivity in 57% of patients with asymptomatic
CD infection,11 suggesting that, in the presence of colitis
with tissutal CMV isolation, CD-toxins EIA positivity
could be a non-diagnostic finding. On the basis of these
considerations, CD colitis was categorized as a possible
disease in our patient, and we decided to start combined
antiviral and antimicrobial therapy. 
Abdominal infectious diseases are common in patients
with acute leukemia receiving standard chemotherapy,
and bacterial and fungal enterocolitis are much more fre-
quent than viral colitis.8,12 However, a proven diagnosis of
viral colitis is difficult to obtain. Relevant to this, CMV
gastrointestinal disease can be only defined by the histo-
logic demonstration of CMV on biopsy materials
obtained by endoscopy..6 The importance of searching for
the viral involvment in hematological patients with
severe colitis, even in the presence of other pathogens,
has been underlined by the case, described by Kottaridis
et al.,13 of an autologous BMT recipient who developed
life-threatening diarrhea associated with fecal CD toxins
and bowel pseudomembranes but unresponsive to initial
oral metronidazole. Because of the worsening of the clin-
ical conditions of the patient, a second colonoscopy with
rectal biopsy was performed, allowing the definitive diag-
nosis of CMV colitis, for which the patient was success-
fully treated with antivirals. Similarly, in our patient,
urgent endoscopic biopsy evidenced CMV colitis that,
otherwise, could have been diagnosed with delay, as a
consequence of the misleading detection of CD toxins. 
While allogeneic bone marrow recipients and even
autologous recipients of selected CD34 positive cells
should be treated with anti-virals at any level of antigen-
emia,14 information about the clinical relevance of low-
level antigenemia in patients receiving standard
chemotherapy is scarce. The detection of 2 positive
cells/slide in our case of biopsy proven CMV colitis sug-
gests that low-level antigenemia should not be over-
looked but considered as a possible indicator of CMV dis-
ease in patients with severe hemorrhagic diarrhea during
standard chemotherapy for hematologic malignancies.
Therefore, we think that even a low-level positivization
of CMV antigenemia could be decisive to perform urgent
endoscopy with biopsy and, whenever invasive diagnos-
tic tools are not promptly feasible, this could become a
hint for evaluation of empirical antiviral treatment in
patients in whom no other pathogens have been identi-
fied or previous specific antimicrobial therapy has failed.
Of interest, Mori et al.15 reported that all the examined 19
allogeneic hematopoieitic stem cell transplant patients
with the CMV gastrointestinal disease developed positive
CMV antigenemia tests during their clinical course, with
the values remaining at a low-level in 9 patients (47%).
However, only 4 of these 19 patients (21%) developed a
positive CMV antigenemia test before developing the
CMV gastrointestinal diseases, suggesting that CMV anti-
genemia testing has limited value in prediction or early
diagnosis of the CMV gastrointestinal disease after BMT.
Real-time PCR could have a more diagnostic significance
in this setting, being this test positive in 50% of the
patients, before the developing of CMV gastrointestinal
disease.15 In conclusion, our case shows that not only
BMT recipients or AIDS patients, but also acute leukemic
patients can develop severe CMV colitis while receiving
the first standard induction chemotherapy. A direct impli-
cation of our observation is that IC patients affected with
severe hemorrhagic diarrhea should be considered for
endoscopic bowel examination and tissutal search for
CMV, even if fecal CD toxins are positive, in order to
obtain a reliable diagnosis and start proper treatments as
soon as possible. The successful clinical outcome in our
patient suggests that, despite the occurence of a severe
CMV ulcero-hemorrhagic colitis followed by a CMV
pneumonia during and immediately after the induction
chemotherapy course, autologous BM/PBSC transplant
procedures can be safely performed in leukemic patients.
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Figure 1. A. Endoscopic presentation of the severe colitis.
Transverse colon: large ulceration with raised edges and irregular
borders, indicated by arrows. B. Immunostaining of colonic biopsy.
Cluster of giant cells with large intranuclear CMV inclusions (orig-
inal magnification, x40; counterstaining with Giemsa). Inset: typi-
cal owl eyes aspect of a CMV infected cell (original magnification,
x100; counterstaining with Giemsa).
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